BioSpace News Archive

Total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024.

Digital clinical diagnostics and diabetes home testing provider Digostics revealed the results from its ground-breaking gestational diabetes mellitus remote screening collaboration with University Hospital Southampton NHS Foundation Trust, a partnership that saw expectant mothers in Hampshire become the first globally to access the gold standard oral glucose tolerance test without needing to attend clinic.

Turnstone Biologics Corp. announced that members of its senior management team will participate in the following investor conferences.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia.

DarioHealth Corp. announced that it has acquired Twill, Inc., a leader in digital-led care. The combination enables Dario to create one of the most comprehensive digital offerings in the market for chronic conditions, spanning a wide spectrum of health and well-being needs from emotional health to the costliest chronic conditions.

BD announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home.

United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter and year ended December 31, 2023.

Immunocore Holdings plc today announced that it will report full year 2023 results, before the US markets open on Wednesday, February 28, 2024.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies.

On October 27, the Company gave notice that an extraordinary general meeting was to take place on November 21.